https://www.thebodypro.com/category/atripla-pro/tag/news

The Latest

Promo Image

Atripla's Co-Pay Program Now Saves More Money

The co-pay program for Atripla now eliminates the requirement that people first pay $50 out-of-pocket before financial assistance begins. The same is true for the drugs that make up Atripla (Sustiva and Truvada), as well as the medications that make ...

Promo Image

The Once and Future King: What Will Replace Atripla Atop the First-Line HIV Treatment Realm?

Gerald Pierone Jr., M.D.

Atripla (which is a combination of efavirenz + tenofovir + emtricitabine) is the acknowledged king in the realm of first-line antiretroviral therapy.  Le Roi est mort, vive le Roi!  Not so fast: The king still breathes. But ...

Promo Image

Atripla Label Update Reflects New Efficacy, Safety and Resistance Data in Treatment Experienced Patients

On January 7, 2010, FDA approved an updated Atripla label including new efficacy, safety and resistance data in treatment experienced patients from a trial (Study 073: A Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tole...

Promo Image

Australia: New HIV Drug Added to Taxpayer-Subsidized List

On Jan. 1, Australia's Pharmaceutical Benefits Scheme added the AIDS drug Atripla (efavirenz, emtricitabine, and tenofovir) to the drugs that are covered for HIV/AIDS patients. The additional cost to the program is expected to be about $15 million (U...

Promo Image

Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce

New York, NY and Foster City, CA -- Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced they have obtained data supporting bioequivalence of a new formulation of the fixed-dose combination of Bristol-Myer...

Promo Image

Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone

Gilead on Tuesday announced that its reformulation of a fixed-dose combination antiretroviral drug combining the company's Truvada with Bristol-Myers Squibb's drug Sustiva is not bioequivalent to the two drugs when used separately, AFX International ...